Free Trial

Bioventix (LON:BVXP) Stock Price Passes Above 50-Day Moving Average - Here's Why

Bioventix logo with Medical background

Bioventix PLC (LON:BVXP - Get Free Report)'s share price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 2,713.11 ($36.81) and traded as high as GBX 2,800 ($37.99). Bioventix shares last traded at GBX 2,655 ($36.02), with a volume of 1,838 shares trading hands.

Bioventix Stock Performance

The company has a market cap of £139.02 million, a price-to-earnings ratio of 17.17 and a beta of 0.35. The firm's 50 day simple moving average is GBX 2,713.11 and its 200-day simple moving average is GBX 2,945.64.

Bioventix (LON:BVXP - Get Free Report) last released its earnings results on Monday, March 31st. The biotechnology company reported GBX 72.27 ($0.98) EPS for the quarter. Bioventix had a net margin of 59.51% and a return on equity of 69.09%. As a group, sell-side analysts expect that Bioventix PLC will post 166.3066955 EPS for the current fiscal year.

Bioventix Cuts Dividend

The company also recently announced a dividend, which was paid on Friday, April 25th. Shareholders of record on Thursday, April 10th were given a dividend of GBX 70 ($0.95) per share. This represents a yield of 2.95%. The ex-dividend date was Thursday, April 10th. Bioventix's dividend payout ratio is 102.19%.

Insider Activity at Bioventix

In other news, insider Bruce Hiscock acquired 31 shares of the company's stock in a transaction on Monday, April 28th. The stock was purchased at an average cost of GBX 2,632 ($35.71) per share, with a total value of £815.92 ($1,107.08). 8.02% of the stock is owned by corporate insiders.

Bioventix Company Profile

(Get Free Report)

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bioventix Right Now?

Before you consider Bioventix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.

While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir at All-Time Highs: Take Profits or Hold the Line?
3 Tech Stocks Insiders Are Buying: Speculative Plays for June
3 Defense Stocks Set to Crush the S&P This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines